On Friday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $116.59 which represents a slight increase of $1.29 or 1.12% from the prior close of $115.3. The stock opened at $115.

Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...

On Thursday, Abbott Laboratories (ABT) stock saw a decline, ending the day at $115.3 which represents a decrease of $-1.50 or -1.28% from the prior close of $116.8. The stock opened at $117.49 and ...

Two resulted in verdicts against the formula companies, totaling $495 million against Abbott Laboratories and $60 million ...

The infant formula manufacturers were facing $6.2bn in punitive damages over allegations their infant formula products caused ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

Hundreds of lawsuits allege Abbott Laboratories’ formula for premature infants made babies sick. But is the formula to blame?

At least two people were killed and six others injured with gunshot wounds after a teenage shooter opened fire in two locations in downtown Orlando where large crowds had gathered to celebrate ...

The decision marks the first victory for the companies as they face more than 1,000 similar cases and previously lost trials, one of which ended with a $500 million verdict.

A jury ruled on Thursday that Abbott Laboratories (NYSE:ABT) and Mead Johnson, a division of Reckitt Benckiser (LON:RKT), are not liable for a young boy's severe intestinal disease, marking a ...

Two resulted in verdicts against the formula companies, totaling $495 million against Abbott Laboratories and $60 ... Chairman and CEO Robert Ford warned, “If the regulatory process is ...